510(k) for Clinical Screening: What It Means

When a facility evaluates an AI clinical screening tool, the first question is usually “Is it FDA approved?” The answer is almost always no — because FDA approval (PMA) is not the regulatory pathway for most clinical AI software. FDA device establishment registration is. And the distinction matters. Most voice biomarker AI tools on the market have no regulatory status at all. The few that do are cleared for a single condition within a single clinical category. Understanding what FDA device establishment registration actually requires — and what it does not — is essential for any medical director or compliance officer evaluating screening technology.

What FDA device establishment registration Actually Means

FDA device establishment registration means the platform has been validated against a legally marketed predicate device through a regulatory pathway that requires demonstrated safety and effectiveness. It is not FDA approval. It is not an endorsement. It means the manufacturer has submitted evidence that the device is substantially equivalent to a device already on the market — and that adverse event reporting is a regulatory obligation, not a policy choice. For the medical director or compliance officer evaluating a clinical AI tool, 510(k) is the minimum regulatory standard that separates regulated clinical software from unregulated wellness applications. Tools without it operate outside the regulatory framework entirely.

The Voice Biomarker Regulatory Landscape

Most voice biomarker AI tools are built to screen for a single condition — depression, cognitive decline, or pulmonary function. Each addresses one clinical category using one signal type. Each requires its own session, its own documentation, its own coding. Traditional tools like the MMSE, MoCA, and PHQ-9 follow the same single-condition pattern but add 15–30 minutes of trained staff time per assessment. The regulatory landscape reflects this fragmentation: existing FDA-registered voice tools cover one condition within one organ system. No single-condition tool provides a complete clinical picture from one patient interaction.

What Multimodal FDA-registered Screening Looks Like

GIA® by Scienza Health is FDA-registered and screens for 46 cognitive, behavioral, and neurological conditions in a single patient conversation lasting 40 seconds. The platform combines voice biomarkers, computer vision, and speech analysis — multimodal, not single-signal. From 40 seconds of natural speech, GIA® analyzes 2,500+ biomarkers while simultaneously tracking facial micro-expressions and movement patterns. Structured medical notes, CPT codes, biomarker results, and session video are prepared for clinician review and submission to the EHR. The clinician authorizes every record. The platform operates under 14 governance domains with 8 verified test cases and 0 silent failures, validated across 19 peer-reviewed studies from Beth Israel Deaconess, NIH, and MIT. GIA® by Scienza Health’s FDA device establishment registration and Samsung strategic technology partnership were recognized by McKnight’s Senior Living in October 2025.

Conclusion

FDA device establishment registration is not a marketing claim. It is a regulatory obligation that governs how a clinical AI tool is built, tested, monitored, and reported on. For facilities evaluating screening technology, it is the line between regulated clinical software and everything else. See the full regulatory details. Review the governance framework.